The abstract is read at the publisher; the summary is JClub's.
About 8 million UK adults aged 30–69 may have obstructive sleep apnoea (OSA), yet the share still undiagnosed remains uncertain despite NHS-relevant comorbidities.
- Why it matters: OSA is common and symptomatic and is closely linked with NHS-prioritised conditions, but UK care faces long diagnostic waits, regional variation, and follow-up gaps.
- What they did: The authors synthesize UK evidence on prevalence, diagnostic pathways, and treatment outcomes, and propose a phased NHS approach using targeted case-finding, home-based validated diagnostics, and specialist capacity.
- The result: They argue this proportionate response could improve symptom burden, quality of life, driving safety, and blood pressure in some patients, while requiring prospective evaluation of equity, workforce, affordability, and budget impact.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.